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AbstrACt
Introduction The increasing prevalence of type 2 
diabetes mellitus (T2DM) presents a significant burden on 
affected individuals and healthcare systems internationally. 
There is, however, no agreed validated measure to infer 
diabetes severity from electronic health records (EHRs). We 
aim to quantify T2DM severity and validate it using clinical 
adverse outcomes.
Methods and analysis Primary care data from the 
Clinical Practice Research Datalink, linked hospitalisation 
and mortality records between April 2007 and March 2017 
for patients with T2DM in England will be used to develop 
a clinical algorithm to grade T2DM severity. The EHR-
based algorithm will incorporate main risk factors (severity 
domains) for adverse outcomes to stratify T2DM cohorts 
by baseline and longitudinal severity scores. Provisionally, 
T2DM severity domains, identified through a systematic 
review and expert opinion, are: diabetes duration, glycated 
haemoglobin, microvascular complications, comorbidities 
and coprescribed treatments. Severity scores will be 
developed by two approaches: (1) calculating a count 
score of severity domains; (2) through hierarchical 
stratification of complications. Regression models 
estimates will be used to calculate domains weights. 
Survival analyses for the association between weighted 
severity scores and future outcomes—cardiovascular 
events, hospitalisation (diabetes-related, cardiovascular) 
and mortality (diabetes-related, cardiovascular, all-cause 
mortality)—will be performed as statistical validation. The 
proposed EHR-based approach will quantify the T2DM 
severity for primary care performance management and 
inform the methodology for measuring severity of other 
primary care-managed chronic conditions. We anticipate 
that the developed algorithm will be a practical tool for 
practitioners, aid clinical management decision-making, 
inform stratified medicine, support future clinical trials and 
contribute to more effective service planning and policy-
making.
Ethics and dissemination The study protocol was 
approved by the Independent Scientific Advisory 
Committee. Some data were presented at the National 
Institute for Health Research School for Primary Care 
Research Showcase, September 2017, Oxford, UK and the 
Diabetes UK Professional Conference March 2018, London, 
UK. The study findings will be disseminated in relevant 
academic conferences and peer-reviewed journals.
IntroduCtIon  
The worldwide prevalence of diabetes mellitus 
is increasing with WHO estimating that over 
422 million adults had diabetes in 2016 with a 
growth in the global prevalence from 4.7% in 
1980 to 8.5% in 2014.1 2 In the UK, the prev-
alence of type 2 diabetes mellitus (T2DM) 
has nearly doubled between 2004 and 2014.3 4 
People with diabetes have a higher risk for 
morbidity and mortality when compared with 
individuals without diabetes,3 5 and hence the 
increasing prevalence presents a significant 
burden on healthcare resources. Diabetes 
management expenses are estimated to 
strengths and limitations of this study
 ► This is the first UK-based study to develop a diabe-
tes severity scoring tool based on real-world elec-
tronic healthcare data to grade people with type 2 
diabetes by their clinical severity.
 ► The study will include a large sample size and use 
high-quality medical data routinely  collected from 
general practices with access to linked national hos-
pitalisation and cause-specific mortality data sets.
 ► The association between the computed severity 
scores and future adverse outcomes (cardiovascular 
event, hospitalisation and mortality) will be used to 
validate the developed severity algorithm.
 ► There is a possibility to miss other severity indica-
tors not recorded in the data sources used such as 
pharmacy dispensing data.
 ► Given that the linkage scheme is only available for 
consented general practices in England, the study 
cohort will be restricted to eligible patients registered 
within England (form nearly 58% of total Clinical 
Practice Research Datalink general practices).
 o
n
 19 Septem
ber 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2017-020926 on 30 June 2018. Downloaded from 
2 Zghebi SS, et al. BMJ Open 2018;8:e020926. doi:10.1136/bmjopen-2017-020926
Open access 
consume up to 11% of the total healthcare budget in the 
UK and USA.6 7 Diabetes is a complex metabolic condi-
tion, of an increasing severity,8 9 at individually varying 
levels, and progressive development of vascular compli-
cations and end organ damage over time. Diabetes is 
mainly managed in primary care in the UK,10 overall 
Europe,11 USA12 and Asia.13 14 In the UK, nearly 75% of 
the diabetes-associated costs relate to management of 
diabetes-related complications.6 
The ‘severity’ of clinical conditions can be conceptual-
ised as a progression of the underlying disease process. 
Increasing disease severity and development of associ-
ated complications lead to greater treatment complexity 
and clinical impact. The severity of chronic conditions, 
such as diabetes, has not been widely considered despite 
the clinical relevance and its likely impact on healthcare 
systems, where few studies have assessed disease severity 
among patients with T2DM or have quantified temporal 
trends or scores of severity.15 16
Severity scores could be clinically useful, particularly in 
T2DM; as such, a new summary score could contribute 
above what existing risk scores offer (eg, moving beyond 
risk for death) and also be highly relevant for use in six 
main clinical and research areas: (1) identifying complex 
patients with a higher need for future care; (2) identi-
fying patients at early stages of disease (benchmarking); 
(3) providing information that will directly inform clin-
ical care; (4) identifying trajectories in severity over time; 
(5) supporting research, for example, by serving as an 
important diabetes-specific covariate to consider in anal-
yses, similarly to the Charlson Comorbidity Index, or 
as an outcome; and (6) providing data that will inform 
resource allocation in health systems, such as the National 
Health Service.
Here, we describe the conceptual development of a 
T2DM severity algorithm model, using electronic health 
records (EHRs) on clinical consultations and treatments. 
Our aim is to use routinely collected clinical and admin-
istrative data to develop a scoring tool which would quan-
tify and grade the severity of T2DM. This model could 
potentially be used by clinicians to stratify patients based 
on disease severity and we aim to demonstrate potential 
advantages over similar risk scores. To validate the algo-
rithm, our secondary aim is to examine the association of 
severity grades with risk of three main adverse outcomes: 
cardiovascular disease, hospitalisation and mortality. The 
developed severity stratification algorithm is anticipated 
to have direct impact on clinical practice and have wider 
implications on service planning and policy-making.
MEthods And AnAlysIs
data source
This study will use data from the Clinical Practice Research 
Datalink (CPRD). The CPRD is one of the world’s 
largest EHR with anonymised primary care records 
from over 650 general practices over the UK.17 Nearly 
76% of all CPRD-registered patients are in England.17 
CPRD data include clinical diagnoses, prescribed thera-
pies, biochemical test results and referrals to healthcare 
services. The accuracy and completeness of diagnostic 
coding and validity of CPRD data, in clinical research, 
have been reported as excellent with positive predic-
tive values (PPVs) of over 90% for nearly 14 conditions 
(including diabetes and cerebrovascular disease).18 PPVs 
were defined as the proportion of CPRD diagnoses that 
were validated as true cases when compared with a gold 
standard such as general practitioner (GP) questionnaire 
or primary care records.
Two metrics for research quality data, recommended to 
be used by researchers, are available for CPRD records.17 
For patient-level data, the flag ‘acceptable’ indicates that 
a patient’s record has met certain quality standards such 
as registration status, valid age and gender and record of 
patient events. For practice-level data, the up-to-standard 
(UTS) date is used as a data quality measure. The UTS 
date is calculated for each CPRD general practice as the 
latest date at which the general practice meets minimum 
quality criteria based on two central concepts: the conti-
nuity of recorded data and the number of recorded 
deaths, in comparison to an expected national range.17 19
Nearly 75% of general practices in England (approxi-
mately 58% of all CPRD practices) have consented to the 
CPRD Linkage Scheme for access to a number of linked 
data sets and national disease registries.17 These include 
hospital data (including outpatient, admissions and acci-
dent and emergency (A&E) data), mortality records (held 
by the Office for National Statistics (ONS)), socioeco-
nomic status and the cancer registry. The linked hospi-
talisation records, held by the Hospital Episode Statistics 
(HES), provide ethnicity data, admission and discharge 
dates, clinical diagnoses and procedures during hospital-
isation recorded using the 10th revision of the Interna-
tional Classification of Diseases (ICD-10) and operating 
procedure codes. This study will only include patients 
registered with English general practices which provide 
UTS data and which participate in the CPRD Linkage 
Scheme.
study population
The study cohort will include individuals aged 35 years 
or over with T2DM (with ≥1 diagnostic code as in (online 
supplementary table S1) between 1 April 2007 and 
31 March 2017. Patients with an ever record of type 1 
diabetes (see online supplementary table S2) will be 
excluded unless they have records of non-insulin anti-di-
abetic therapies. We chose the study period after 2006 as 
the quality of CPRD data has improved substantially to 
adhere with the then introduced important changes to 
the national incentive scheme The Quality and Outcomes 
Framework (QOF), an incentivisation programme for all 
GP surgeries in the UK.20 21 QOF exception reporting 
process allows general practices to exclude patients 
from indicators or a clinical domain based on discre-
tionary exception codes. However, evidence on the use 
of exception codes has shown that they are being used 
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appropriately by practices and overall exception rates for 
diabetes patients are low.22
For this cohort construction, we will consider imple-
menting previously validated algorithms designed to 
identify diabetes cases by avoiding potential misclassifica-
tion in routinely collected data such as CPRD.23 24 Eligible 
patients will be followed up until censored at the earliest 
instance of any of the following event dates: patient trans-
ferred out of the practice (any cause), last collection date 
for the practice, the study end on 31 March 2017 or death. 
The main demographic and clinical characteristics of the 
defined diabetes cohorts (such as age, gender, geographic 
region within England, patient-level and general prac-
tice-level social deprivation, body mass index (BMI) and 
baseline glycated haemoglobin (HbA1c)) will be identi-
fied. Based on our previous studies, the expected sample 
size in a year will include 11 000 patients with T2DM regis-
tered with English general practices linked to the HES 
Admitted Patient Care data set, HES Outpatient and HES 
A&E data sets. A random 80% of the identified diabetes 
cohort (training dataset) will be used to develop the 
severity tool, with the remaining 20% of the cohort used 
as a validation data set, as described below.
severity domains
A systematic literature search for studies that developed 
algorithms or models to assess and quantify the severity 
of diabetes was conducted to identify the domains and 
subdomains for T2DM severity (to be published sepa-
rately). Also, expert clinical opinion from members of the 
research team was used to supplement the search process 
and identify possible omissions. Clinical members in the 
team include pharmacists (DMA, SSZ), GPs (CS, CM, 
CACG, HVm and NQ), a consultant diabetologist (MKR) 
and a consultant cardiologist (MM), who used their 
expertise to create a list of relevant clinical domains for 
T2DM severity. The final domains to be included in the 
severity model will be decided during the analysis stage. 
Currently, the identified clinical domains that are relevant 
to the degree of progression of T2DM include: patient 
factors (diabetes duration (the period between T2DM 
diagnosis and the severity score estimation) and BMI), 
monitoring laboratory tests (HbA1c categories (threshold 
of 7% [53 mmol/mol]), and blood glucose levels), type 
of anti-diabetic therapy, other prescribed medications 
(such as lipid-regulating medications and ACE inhibi-
tors (ACEIs)), comorbidities (including diabetes-related 
complications, depression), hospitalisation and surgical 
interventions. Comorbidities will be identified using 
appropriate code lists and contribute to the severity score 
according to each score computing method. The identi-
fied domains and subdomains are described in table 1. 
Domains will also be reviewed by a panel of ‘experts by 
experience’ (people with lived experience of T2DM) to 
provide patient validation of the severity scoring tool.
The clinical Read codes for the defined severity domains 
codes and the product codes for drug therapies will be 
identified using the (pcdsearch) Stata user command.25 
The (pcdsearch) command is a search programme devel-
oped to extract code lists from typically very long lookup 
files associated with primary care databases using an 
input file containing a list of stubs for codes of interest 
to be searched for. For CPRD, the lookup files Medical 
data set is searched for all clinical Read codes and the 
Product lookup file, that includes unique product codes, 
is searched for all treatments. The corresponding ICD-10 
codes will be used to identify clinical domains recorded 
in the hospitalisation data and ONS mortality records. 
The relevant CPRD operational identification entities for 
the laboratory tests will be identified. This is an ongoing 
process whereby the final lists of domains and codes will 
be reached by consensus among the clinical members of 
the team. All code lists will be available on the online clin-
ical code repository ( ClinicalCodes. org).26
study outcomes
The adverse outcomes of interest will be the development 
of the first event among cardiovascular disease (myocardial 
infarction, stroke), future hospitalisation (any hospitalisa-
tion, diabetes-related and cardiovascular hospitalisation) 
and death (diabetes-related mortality, cardiovascular 
mortality and all-cause mortality). Secondary outcome will 
be future hospitalisation due to hypoglycaemia, a relevant 
and potentially preventable adverse outcome. The hospi-
talisation and death outcomes will be identified using the 
linked HES and ONS mortality data, respectively. Simi-
larly with severity domains, Read codes and ICD-10 codes 
(available on the  ClinicalCodes. org online repository) 
will be used to identify the outcomes as appropriate.
statistical analyses
Diabetes severity algorithm
Using annual data bins and grouping diabetes patients 
in the training data set (include random 80% of the total 
diabetes cohort) from 1 April to 31 March between 2007 
and 2017, the developed diabetes algorithm will grade 
the severity of T2DM using predefined (sub)domains. 
Our study period (after 2006) was selected to ensure very 
high data quality in primary care, while the addition of 
secondary care data will make our analyses even more 
robust, in terms of accurately classifying T2DM severity 
levels.
We will consider two approaches to derive numerical 
or categorical diabetes severity scores or levels. First, 
we will use a binary classification (severity indicator: 
present/absent) within each subdomain and calculate 
an aggregate score. The second approach, through hier-
archical stratification of end organ microvascular and 
macrovascular complications, will involve increasing 
weighting within each subdomain, as severity increases 
where scores of 1, 2 or three on each subdomain will be 
assigned based on clinical input in terms of severity. Then, 
regression models, using death (primary outcome) and 
future hospitalisation (secondary outcome) as depen-
dent variable, will be fitted from which the weights of 
its estimates will be used to calculate the weights for 
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severity subdomains. The highest possible severity score 
will be known when the final list of included domains 
and subdomains is decided. Hierarchical diagrams 
of the clinical severity of identified diabetes-related 
complications domains (figure 1), cerebrovascular 
domains (figure 2) and cardiovascular (figures 3 and 4, 
Table 1 The main (sub)domains identified to quantify the severity of type 2 diabetes
Severity domain Severity subdomain
1. Risk factors*  ► Duration of type 2 diabetes40
 ► Body mass index (BMI)
 ► Hypertension
 ► Hyperlipidaemia
 ► Personal/Family history of cardiovascular disease
 ► Blood glucose levels
 – Glycated haemoglobin (HbA1c)
35
 – Fasting blood glucose (FBG) and random blood 
glucose (RBG) 
2. Type/pattern of anti-diabetic treatment, insulin use and 
other therapies
 ► Anti-diabetic therapy ever;40 Therapies with cardiovascular 
benefits versus other; Changes in drug treatments;43 or the 
number of prescribed treatments42
 ► Insulin use: prescription ever or within 1 year of diagnosis; 
Insulin initiation:15 time to initiation
 ► Other therapies: ACE inhibitors (ACEI) and lipid-regulating 
therapies
3. Diabetes-related microvascular complications15 34  ► Neuropathy (foot ulcer, Charcot foot, gangrene, amputation)
 ► Nephropathy
 ► Retinopathy (laser therapy and blindness)
4. Renal disease  ► Microalbuminuria and proteinuria
 ► Moderate-severe chronic kidney disease (CKD) stages 3 
and 434
 ► End-stage renal disease (ESRD): kidney transplant and 
dialysis
5. Cardiovascular and cerebrovascular disease  ► Atherosclerosis15 34
 ► Myocardial infarction (MI)15 34
 ► Angina15 34
 ► Atrial/ventricular fibrillation (AF)/(VF)34
 ► Heart valve disease
 ► Heart failure (HF)34
 ► Peripheral vascular disease (PVD)34
 ► Transient ischaemic attack (TIA)
 ► Ischaemic stroke, haemorrhagic stroke15 34
6. Cardiovascular and cerebrovascular interventions  ► Coronary artery bypass graft (CABG)
 ► Coronary artery interventions (PCI/PTCA)
 ► Endovascular aneurysm repair (EVAR)
 ► PVD stenting and bypass procedures
 ► Heart valve interventions
 ► Use of defibrillator
 ► Carotid artery events, stenting and bypass interventions
7. Other comorbidities  ► Anxiety
 ► Depression
 ► Dementia
 ► Cognitive impairment
8. Hospital admissions  ► Any-cause hospital admissions
 ► Diabetes-attributable admission
 ► Cardiovascular disease-related admission
9. Emergency diabetes-related events  ► Hypoglycaemia
 ► Hyperosmolar hyperglycaemic state (HHS)34
 ► Diabetic ketoacidosis (DKA) or other coma34
*Other demographic data (such as age, gender and the level of deprivation) are important predictors for adverse outcomes and will be 
included in the later risk prediction analysis.
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Figure 1 Severity hierarchy of diabetes-related microvascular complications. CKD, chronic kidney disease; ESRD, end-stage 
renal disease.
Figure 2 Severity hierarchy of cerebrovascular domains. TIA, transient ischaemic attack.
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online supplementary figures S1 and S2) domains are 
presented.
Subdomains with many measurements over time, 
such as HbA1c levels and BMI, will be modelled as time-
varying covariates (alternative models will be considered 
to account for non-linear changes). Within each time 
window, the average of these measurements will be used, 
and we will also use multiple imputation approaches to 
account for missing data. Provisionally, we will consider 
using data records within look-back periods between 
3 and 5 years. Different look-back windows within this 
period will be tested to obtain the optimal time window. 
Descriptive statistics of the study population and the esti-
mated scores will be performed.
Severity algorithm validation
When we have developed a first version of the severity 
score tool, it will be validated statistically by quantifying the 
association of severity scores to future adverse outcomes. 
The primary outcome will be developing a cardiovascular 
event (myocardial infarction, stroke), future hospitalisa-
tion and death (diabetes-related mortality, cardiovascular 
Figure 3 Severity hierarchy of coronary and vascular domains. CABG, coronary artery bypass graft; EVAR, endovascular 
aneurysm repair; HF, heart failure; MI, myocardial infarction; PAD, peripheral arterial disease; PCI, percutaneous coronary 
intervention; PVD, peripheral vascular disease. 
Figure 4 Severity hierarchy of cardiovascular disease domains (heart rate, rhythm and conduction). VF, ventricular fibrillation; 
VT, ventricular tachycardia.
 o
n
 19 Septem
ber 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2017-020926 on 30 June 2018. Downloaded from 
7Zghebi SS, et al. BMJ Open 2018;8:e020926. doi:10.1136/bmjopen-2017-020926
Open access
mortality and all-cause mortality). A secondary adverse 
outcome will be future hospital admission due to hypo-
glycaemia, a relevant and potentially preventable adverse 
outcome. Cox proportional hazards (after assessing 
proportional hazards assumption) and/or compet-
ing-risks regressions will be used to perform survival 
analyses and assess the relationship between the severity 
score and outcomes controlling for all available patient 
characteristics (such as age, gender, ethnicity and level 
of social deprivation). We aim to analyse and assess how 
severity scores differ across different levels of these vari-
ables. As stated earlier, a random 20% of the study cohort 
(validation data set) will be used to validate the perfor-
mance of the severity algorithm that was developed in the 
training data set (80% of the diabetes cohort). Using the 
calculated subdomains weights (derived by the regression 
model estimates), Cox regression analysis will be used 
to validate the developed severity algorithm and we will 
assess the model performance using relevant measures 
(such as area under the receiver operating characteristic 
curve). Using this analysis, we will also test how much 
the 'sophisticated' full model that includes all relevant 
severity domains will add in terms of predictive validity of 
the adverse outcomes over a simpler model that includes 
demographic data (age, gender and level of social depri-
vation) alone.
Longitudinal trends of diabetes severity
In patients newly diagnosed with T2DM, during the study 
period, we will assess the temporal trends of severity 
scores over time by calculating the time needed to prog-
ress along the quintiles of the severity scale starting from 
the date or year of diagnosis and identify the predictors to 
this progression across quintiles.
While the inclusion of some domains such as carotid 
artery stenting, the use of ACEIs or lipid-regulating 
drugs, kidney transplantation and laser therapy are clin-
ically relevant and represent markers of greater level of 
disease severity, they also improve the prognosis (lessen 
the grade of severity), that is, raising a risk of ‘feedback’. 
While we will further assess their role, we may have to not 
include these domains in the modelling at the analysis 
stage. All statistical analyses will be conducted using Stata 
Statistical Software for Windows: Release 15 (StataCorp 
LP, College Station, Texas, USA).
Patient and public involvement and engagement
The public interest in the reuse of routinely collected elec-
tronic health data for research purposes has expanded 
over recent years. Our study presents a valuable oppor-
tunity to address the challenge of how to develop mean-
ingful and productive patient and public involvement 
and engagement (PPIE) collaborations in observational 
studies that make use of secondary data.
We will identify suitable PPIE partners to collaborate 
on this study and develop creative strategies for mean-
ingful involvement as the project develops. Participants 
to provide their input that will be particularly valuable 
for deciding what information would be most useful to 
patients with diabetes and for providing feedback into the 
developed diabetes algorithms.
In the latter stages of the study, jointly with our PPIE 
partners, we will plan and deliver a patients’ and carers’ 
workshop where we will present emerging findings and 
seek feedback to inform further work and the dissemi-
nation strategy. This will include an exercise around 
weights of domains within the algorithm. PPIE work will 
be reported using the GRIPP (Guidance for Reporting 
Involvement of Patients and Public) checklist.27
dIsCussIon
The global and country-specific prevalence of diabetes has 
increased substantially.2 28–31 For T2DM, prevalence rates 
have doubled over the past two decades.4 32 33 Diabetes 
diagnosis is associated with higher risk for morbidity and 
mortality in comparison to people without diabetes.5 
Despite the natural progression of most chronic diseases, 
including T2DM, and their important clinical impli-
cation on prognosis and medical resources utilisation, 
only a few studies have attempted to grade the severity of 
chronic conditions over time. Our proposed study aims to 
develop a contemporary algorithm to quantify the severity 
of T2DM, a highly prevalent condition, using routine 
EHR. The scoring tool will be based on clinically relevant 
diagnoses and treatments modelled as severity domains 
and subdomains. The algorithm will enable clinicians to 
grade patients with T2DM according to the level of their 
disease severity, at baseline and longitudinally, as driven 
by the weights of the included clinical domains.
Prior studies
Currently, there are limited data around validated severity 
measures that can be used in routine clinical practice 
managing patients with T2DM. Consequently, we are in 
parallel finalising a conducted systematic review for clin-
ical-based diabetes severity models which will inform the 
refinement of this work. Here, we discuss three relevant 
diabetes severity measures that have been previously 
reported from countries outside the UK.
In the first study, Gini et al categorised the severity of 
T2DM (n=300) into four levels based on insulin use and 
the presence of diabetes-related complications (see online 
supplementary table S3).15 A validation study in a random 
sample of cases was performed by interviewing their GPs. 
We, however, aim to include more patients with T2DM 
and consider more clinical data such as other coexisting 
conditions, non-insulin therapies, statins and ACEIs that 
have been shown to be associated with reduced risk of 
adverse outcomes.
In the second study, a diabetes symptom checklist was 
created to measure the perceived symptom severity and 
assess the changes over time in 185 patients with T2DM.16 
The checklist contained 34 items categorised by main 
clinical symptoms (see online supplementary table S3). 
The patterns of comorbidities and prescribed treatments 
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were reportedly associated with significant differences 
in the estimated severity scores.16 The sample size was 
however relatively small and the checklist was based on 
patients' perception on diabetes symptoms severity.
Third, Young et al calculated a Diabetes Complications 
Severity Index (DCSI) in 4229 patients with type 1 or type 
2 diabetes in one US geographic region to examine its 
association with adverse outcomes (risk of hospitalisation 
and mortality).34 In comparison to using a simple numer-
ical count of complications, DCSI found to be a better 
tool to predict adverse outcomes. The authors used phar-
macy (insulin use only) and laboratory data to compute 
the severity index and included patients from clinics with 
largest ethnic diversity (see online supplementary table 
S3) . However, the DCSI missed additional domains such 
as diabetes duration, hyperlipidaemia and a wider range 
of diabetes-related and end organ damage manifestations 
that we aim to assess in addition to hospitalisation and 
mortality.
In the wider literature, although several studies have 
investigated the possible role of other various factors on 
the severity of diabetes, none have provided a severity 
scoring tool that uses data from various clinical domains 
as planned in our study that can use the wealth of infor-
mation routinely collected in electronic healthcare 
databases. In these studies, approaches used to define 
diabetes severity included: comparing T2DM severity, 
before and after obesity surgery;35 examining the associa-
tion between diabetes severity and either haematological 
and immunological changes,36 levels of urine citrate,37 a 
biomarker for adverse outcomes;38 grip strength;39 or the 
use of complementary medicine to manage T2DM.40
Overall, the severity of T2DM has been previ-
ously assessed using the following domains: the complexity 
of anti-diabetic treatment regimens35 or HbA1c levels;
37 a 
summary severity variable that includes vascular compli-
cations;41 or a health status composite, number of comor-
bidities and patterns of treatments.42 43 Other putative 
and less clinically robust indicators or animal models 
were reportedly used to assess the severity of T2DM such 
as the effect of different patient education approaches 
on diabetes severity;44 evaluating the effect of parental 
history;45 and the role of genetic,46 47 metabolic48 or 
inflammatory mediators.49
In comparison to our planned study, none of 
the previous studies included as many routinely collected 
clinically relevant variables as in our more inclusive 
summary severity score algorithm or assessed the asso-
ciation of estimated scores with the various adverse 
outcomes included in our defined primary and secondary 
endpoints.
Potential strengths and limitations
Our proposed study has several potential strengths: 
First, it aims to present a contemporary measure to the 
available tools and the first UK-based study to develop 
an EHR-based severity scoring tool to grade patients by 
their T2DM severity. Second, the study uses high-quality 
real-world medical data routinely collected from general 
practices. The use of routinely collected data indicates 
that severity scores can be generated automatically with 
minimal effort. Third, the views of PPIE collaborators 
will be incorporated in the development of the severity 
tool. Fourth, we will access two linked data sets: the hospi-
talisation (HES) data (to maximise data capture and 
reduce condition misclassification), and the cause-spe-
cific mortality data to ascertain causes of death. Fifth, the 
sample size is expected to be large enough to drive the 
development and evaluation of the severity algorithm. 
Sixth, a statistical validation of the developed algorithm is 
planned and described.
As we will use data available in CPRD and HES data sets, 
one of the limitations we anticipate is the possibility to 
miss other severity indicators not recorded in used 
data sets. These include detailed pharmacy data such as 
‘actual’ dispensing and adherence data. Also, the use of 
routinely collected data is associated with missing values, 
being collected from questionnaires, and issues around 
the accuracy of coding. However, we plan to use appro-
priate imputation methods and definite criteria to mini-
mise the effect of coding issues. A possible limitation 
that should be acknowledged is underestimated and 
poorly represented T2DM severity levels for patients not 
regularly attending a general practice, people missing 
appointments or patients not being reliably captured in 
the database due to very high mobility status (eg, home-
lessness). This limitation aligns with QOF exception 
reporting that allows practices to exclude patients from 
indicators or a clinical domain based on discretionary 
exception codes. However, the use of QOF exception 
coding was considered appropriate and its levels were very 
low, especially for informed dissent.22 Another limitation 
is that our study will be restricted to patients registered 
with general practices in England, as CPRD currently 
only provides linkage to external national data sets for 
consented general practices in England. However, English 
general practices form the majority of all CPRD practices 
including nearly 76% of total registered patients.17 Finally, 
due to project time constraints, it is not possible to vali-
date the developed diabetes scores using questionnaires 
(as reported previously15) or replicating the algorithm in 
a separate data set. However, we have planned a statistical 
validation of the developed algorithm.
Importance and the clinical implications of the severity tool
The developed algorithm and severity tool may have 
significant implications for primary care both in terms 
of disease management and resource allocation. Ideally, 
through future work of further validation and assessment 
of clinical utility, the severity tool will be of practical use in 
primary care through its implementation in the clinical 
computing systems used in the UK.50 The clinical signif-
icance of the developed severity algorithm to primary 
care is driven by the inclusion of highly relevant clinical 
domains, such as diabetes-related complications and 
comorbidities, mapped to routinely collected data.
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Additionally, by assessing the longitudinal patterns of 
severity, the developed tool may be more clinically rele-
vant than the currently used proxy (HbA1c), and thus it 
could be a more reliable indicator in informing practices’ 
remuneration for diabetes care. Categorising individuals 
based on their diabetes severity will be relevant for risk 
stratification (which may enable safer delegation of care 
within the clinical team), help identify individualised 
patient risks and will help practitioners triage patients in 
need of a greater clinical input which informs towards 
stratified medicine to reduce future life-changing diabe-
tes-related complications. Moreover, the weights of the 
severity scores may inform future clinical trials as the 
scoring tool considers a broader range of cardiovascular 
conditions than in most randomised clinical trials. Given 
the relatively low rates of cardiovascular outcomes in 
some trials, identifying patients with diabetes who are at 
higher risk via our severity algorithm would help to power 
trials with overall longer-term benefit for patients. Finally, 
the composite severity score may serve as an important 
confounding factor in future research, as an example, to 
match diabetes cases and controls in observational studies 
and clinical trials.
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